Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
PURE Bioscience (PURE) had Stock-Based Compensation of $0.03M for the most recently reported fiscal quarter, ending 2025-10-31.
| Income Statement Financials | |
$0.71M |
|
$-0.46M |
|
$0.26M |
|
$0.45M |
|
$1.09M |
|
$-0.38M |
|
$-0.09M |
|
$-0.46M |
|
$-0.46M |
|
$-0.46M |
|
$-0.46M |
|
$-0.46M |
|
$-0.46M |
|
$-0.38M |
|
$-0.38M |
|
111.89M |
|
111.89M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$1.18M |
|
$0.01M |
|
$0.01M |
|
$1.19M |
|
$3.16M |
|
$3.57M |
|
$3.57M |
|
$6.73M |
|
$-5.55M |
|
$-5.55M |
|
$-5.55M |
|
111.89M |
|
| Cash Flow Statement Financials | |
$-0.25M |
|
-- |
|
$0.35M |
|
$0.41M |
|
$0.51M |
|
$0.10M |
|
|
Stock-Based Compensation |
$0.03M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.37 |
|
-- |
|
-- |
|
-1.81 |
|
-1.02 |
|
63.56% |
|
-53.53% |
|
-53.53% |
|
-- |
|
-65.54% |
|
-65.54% |
|
$-0.25M |
|
-- |
|
-- |
|
-- |
|
0.60 |
|
1.09 |
|
1.82 |
|
49.45 |
|
8.37% |
|
8.37% |
|
-39.12% |
|
23.52% |
|
$-0.05 |
|
$-0.00 |
|
$-0.00 |
|